Lake Street Maintains Buy on Evaxion Biotech, Lowers Price Target to $7

Benzinga ·  Mar 31, 2023 09:28

Lake Street analyst Thomas Flaten maintains Evaxion Biotech (NASDAQ:EVAX) with a Buy and lowers the price target from $18 to $7.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment